<DOC>
	<DOCNO>NCT01774630</DOCNO>
	<brief_summary>Chronic myeloid leukemia ( CML ) hematopoietic neoplasm characterize reciprocal translocation ( 9 ; 22 ) . The result oncoprotein , bcr-abl essential trigger growth survival leukemic cell . In past decade , bcr-abl tyrosine kinase inhibitor ( TKI ) imatinib ( IM Glivec© ) standard care patient CML , induce durable response . However , require continue IM indefinitely ability IM eradicate CML clone uncertain . In small proportion patient , IM induce complete molecular response ( CMR ) define disappearance bcr-abl transcript conventional quantitative RT-PCR . The question whether patient cured discontinue drug therapy assess Mahon coll , STIM study . He demonstrate IM safely discontinue patient CMR least 2 year duration patient relapse IM discontinuation mainly first 6 month respond reintroduction imatinib . Nilotinib rationally design second generation tyrosine kinase inhibitor improve target specificity imatinib . Its efficacy safety treatment patient resistant intolerant imatinib well patient newly diagnose CML-CP lead registration second first line treatment CML-CP patient . Nilotinib produce even faster deep response occurrence CMR Imatinib . Consequently , one assume potent drug nilotinib could induce deep sustain CMR allow long period treatment IM . The objective pilot trial ass Nilotinib rescue STIM patient molecular relapse IM discontinuation provide estimation duration CMR nilotinib discontinuation 2nd line therapy among patient experience 2 year stable CMR nilotinib .</brief_summary>
	<brief_title>Multicenter Single-arm Pilot Study Evaluating Efficacy Nilotinib CML Patients With Molecular Relapse After Glivec Discontinuation Within Context STIM Trials ( STIM STIM2 )</brief_title>
	<detailed_description>Patients CML include STIM trial , stop treatment imatinib signal detectable . In case reappearance transcript Bcr-Abl , patient relapse . The trial Nilo Post STIM suggest patient ass Nilotinib rescue STIM patient molecular relapse IM discontinuation provide estimation duration CMR nilotinib discontinuation 2nd line therapy among patient experience 2 year stable CMR nilotinib . The treatment/strategy study : - Screening - Inclusion/exclusion criterion - CML history - Confirm molecular relapse discontinuation imatinib ( quantitative RT-PCR two consecutive assessment peripheral blood sample ) - Treatment • Nilotinib 300mg BID 2 year - Premature treatment discontinuation study : primary secondary resistance progression accelerate phase blast crisis , AE ( define later ) . - In case unsatisfactory response : transcript stability increase two consecutive PCR : nilotinib blood monitoring , nilotinib dose escalation 400mg BID propose - Discontinuation 2 year patient resume confirmed CMR - Follow-up treatment nilotinib : - Physical exam , basic laboratory parameter , monthly first 3 month every 3 month . - Centralized quantitative RT-PCR Bcr-Abl monthly 6 month every 3 month 24 month - Follow AE management guideline nilotinib reduction/interruptions - Follow-up nilotinib discontinuation - Patients confirm molecular relapse - Physical exam , event collection , basic laboratory parameter ( include glycemic lipid profile ) every 2 month first year every 3 month - Hematology centralize quantitative RT-PCR monthly first year every 3 month 12 month - Patients without confirmed molecular relapse take another treatment ( dasatinib example ) stop follow-up trial</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Male female patient Patient participate STIM trial ( include STIM , STIM2 et EUROSKI ) confirm molecular relapse two consecutive RQ PCR , imatinib discontinuation Still chronic phase Not yet treat relapse At least 18 year old ( upper age limit ) SGOT SGPT &lt; 2.5 UNL Serum creatinin &lt; 2 UNL No plan allogeneic stem cell transplantation Signed informed consent ECOG score 0 2 Pregnancy , lactation Prior concurrent malignancy CML ( exception mention ) Serious uncontrolled cardiovascular disease Severe psychiatric/neurological disease ( previous ongoing ) Ongoing treatment risk induce `` torsades de pointe '' QTcF &gt; 450ms despite correction predispose factor ( i.e electrolytes… ) Congenital long QTcF No health insurance coverage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Treatment , relapse , complete molecular response</keyword>
</DOC>